Increased blood level of urea and creatinine after chemotherapy in breast cancer patients

Uzma Raza; Ali Iftikhar; Aziza Khanam; Sidra Rizwan

doi:10.18203/2320-6012.ijrms20253132

Authors

Uzma Raza Department of Biochemistry, Hamdard College of Medicine, Karachi, Pakistan
Ali Iftikhar Karachi Institute of Medical Sciences, Karachi, Pakistan
Aziza Khanam A1-Tibri Medical College, Isra University Karachi Campus, Karachi, Pakistan
Sidra Rizwan Department of Oncology, Jinnah Postgraduate Medical Centre, Karachi, Pakistan

DOI:

https://doi.org/10.18203/2320-6012.ijrms20253132

Keywords:

Breast cancer, Chemotherapy, Creatinine, Nephrotoxicity, Treatment, Urea

Abstract

Background: Breast cancer is treated with surgery and often combined with chemotherapy, radiotherapy and or hormonal therapy or both. The treatment has some side effects such as hair loss, nausea, fatigue peripheral neuropathy, nephropathy etc. The objective of the study was to assess the nephrotoxic effects after treatment of breast cancer.

Methods: The infiltrating ductal carcinoma patients were treated with surgery, chemotherapy, with or without radiotherapy and hormonal therapy. The non-diabetic, non-cardiac post-menopausal breast cancer patients were further subdivided on the basis of nodes histopathology, with or without lymph node metastasis. Patients were subjected to different combination of disciplines of therapy including radiotherapy, chemotherapy and hormonal therapy. The blood samples were collected before and after chemotherapy. The blood was analyzed for urea and creatinine to assess the nephrotoxicity.

Results: There was a significant increase in blood urea and creatinine levels after the treatment as compared to before the start of therapy.

Conclusions: It is concluded that treatment of cancer (with chemotherapy, radiotherapy, hormonal therapy) lead to nephrotoxicity.

Metrics

Metrics Loading ...

References

Moradi N, Izadi S, Hemmati HR. Renal insufficiency in breast cancer patients; a review study. J Nephropharmacol. 2024;13(2):e11659. DOI: https://doi.org/10.34172/npj.2024.11659

Shen G, Zhao F, Huo X, Ren D, Du F, Zheng F, et al. Meta Analysis of HER 2-enrieched subtype predicting the pathological complete response with in HER 2-positive Breast cancer in patients who received neoadjuvant treatment. Front Ocncol. 2021;11. DOI: https://doi.org/10.3389/fonc.2021.632357

Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol. 2018;22(1):210-44. DOI: https://doi.org/10.1007/s10157-017-1448-z

Boeno FP, Patel J, Montalro RN, Lapierre Nguyen Schreiber CM, Smuder AJ. Effect of exercise preconditioning on Doxorubicin induced liver and kidney Toxicity in male and female Rats. Int. J Mol Sci. 2023;24(12):10222. DOI: https://doi.org/10.3390/ijms241210222

Chen C, Xie D, Gewirtz DA, Li N. Nephrotoxicity in cancer Treatmen: An update. Adv. Cancer Res. 2022;155:77-129. DOI: https://doi.org/10.1016/bs.acr.2022.03.005

Kamal A. Estimation of blood urea and serum creatinine level in patients of renal disorder. IJFALS. 2014;4(4)199-202

Fang CY, Lou DY, Zhou LQ, Wang JC, Yaug B, He QJ, et al. Natural products: potential treatments for as platin induced nephrotoxicity. Acta Pharmacol Sinica. 2021;42(12):1951-69. DOI: https://doi.org/10.1038/s41401-021-00620-9

Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485-505. DOI: https://doi.org/10.1200/JCO.20.03399

Rajan KK, Fairhurst K, Birkbeck B, Novintan S, Wilson R, Savovic J, et al. Overall survival after mastectomy Vevsus breast-conserving surgery with adjuvant radiotherapy for early stage breast cancer Meta-analysis. BJS Open. 2024May 17;8(3):Zrae040. DOI: https://doi.org/10.1093/bjsopen/zrae040

Nguyen SUI, Phan AT, Nguyen LM, Cai H, Tran TV, Shu XO, et al. Chemotherapy induced toxicities and their association with clinical and non-clinical factors among Breast Cancer Patients in Vietnam. Curr Oncol. 2022;29(11):8269-84. DOI: https://doi.org/10.3390/curroncol29110653

Kitai Y, Matsubara T, Funakoshi T, Horimatsu T, Muto M, Yanagita M. Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology. Ren Replace Ther. 2016;2(1):33. DOI: https://doi.org/10.1186/s41100-016-0046-y

Obadipe JA, Samuel TA, Jimoh MA, Folorunso SA. Chemotherapy induced electrolyte disorders, nephrotoxicity in cancer patients from selected Nigerian tertiary care hospital. Niger Med J. 2022;63(3):1196-203.

Hamed KM, Dighriri IM, Baomer AC, Alhar-Thy BT, Alenazai FE, Alali GH, et al. overview of methotrexate toxicity. A comprehensive literature, review. Cureus. 2022;14(9):e29518. DOI: https://doi.org/10.7759/cureus.29518

Cai Z, Samdelov S, Kullak Ublick G, Visentin M. Molecular mechanisms of Colistin induced nephrotoxicity. Molecules. 2019;24(3):653. DOI: https://doi.org/10.3390/molecules24030653

Griffein BR, Faubel S, Edelstein CL. Biomarkers of drug induced kidney toxicity. Ther Drug Monit. 2019;41:213-26. DOI: https://doi.org/10.1097/FTD.0000000000000589

Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltam J, et al. Genetic variation and cisplatin Nephrotoxicity. A systemic reviews. Front Pharm. 2018,27;111. DOI: https://doi.org/10.3389/fphar.2018.01111

Alshanwani AR, Mohamed AM, Faddah LM, Shaheen S, Arafah MM, Hagar H, et al. Cyanocobalamin and/or calcitriol mitigate renal damage-mediated by tamoxifen in rats: Implication of caspase-3/NF-κB signaling pathways. Life Sci. 2021;277:119512. DOI: https://doi.org/10.1016/j.lfs.2021.119512

Halka J, Spaleniak S, Kade G, Antosieioic S, Signorshi D. The nephrotoxicity of drugs used in causal oncological therapies. Curr Oncol. 2022;8:29(12):9681-94. DOI: https://doi.org/10.3390/curroncol29120760